Breaking News Instant updates and real-time market news.

EGRX

Eagle Pharmaceuticals

$59.75 /

-0.25 (-0.42%)

06:54
01/06/20
01/06
06:54
01/06/20
06:54

Eagle Pharmaceuticals, NorthShore University HealthSystem enter research pact

Eagle Pharmaceuticals announced a new research agreement with NorthShore University HealthSystem in Evanston, IL, focused on studying Eagle's RYANODEX for traumatic brain injury in animal models.

EGRX Eagle Pharmaceuticals
$59.75 /

-0.25 (-0.42%)

04/16/19 Cantor Fitzgerald
Eagle agreement with Teva could be worth $5 per share, says Cantor Fitzgerald

TODAY'S FREE FLY STORIES

Upgrade
AP Moller Maersk upgraded to Buy from Hold at Jefferies » 04:44
09/29/20
09/29
04:44
09/29/20
04:44
AMKBY

AP Moller Maersk

$0.00 /

+ (+0.00%)

Jefferies analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMKBY AP Moller Maersk
$0.00 /

+ (+0.00%)

09/28/20 Goldman Sachs
AP Moller Maersk upgraded to Buy from Neutral at Goldman Sachs
09/22/20 JPMorgan
AP Moller Maersk upgraded to Overweight from Neutral at JPMorgan
08/21/20 JPMorgan
AP Moller Maersk downgraded to Neutral from Overweight at JPMorgan
08/20/20 Barclays
AP Moller Maersk price target raised to DKK 8,100 from DKK 6,400 at Barclays
AMKBY AP Moller Maersk
$0.00 /

+ (+0.00%)

Upgrade
Hannover Re upgraded to Outperform from Neutral at Credit Suisse » 04:41
09/29/20
09/29
04:41
09/29/20
04:41
HVRRY

Hannover Re

$0.00 /

+ (+0.00%)

Credit Suisse analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HVRRY Hannover Re
$0.00 /

+ (+0.00%)

09/10/20 Bryan Garnier
Hannover Re upgraded to Buy from Neutral at Bryan Garnier
09/08/20 Barclays
Hannover Re price target raised to EUR 126.40 from EUR 126.20 at Barclays
09/07/20 JPMorgan
Hannover Re upgraded to Overweight from Neutral at JPMorgan
08/11/20 Morgan Stanley
Hannover Re price target lowered to EUR 167 from EUR 170 at Morgan Stanley
General news
FX Action: USD-JPY has remained settled in the mid 105.00s » 04:15
09/29/20
09/29
04:15
09/29/20
04:15

FX Action: USD-JPY has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

General news
FX Action: USD-CAD has remained buoyant » 03:40
09/29/20
09/29
03:40
09/29/20
03:40

FX Action: USD-CAD has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

General news
FX Update: The dollar and yen are softer » 03:00
09/29/20
09/29
03:00
09/29/20
03:00

FX Update: The dollar and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

General news
Asian Market Update: » 01:40
09/29/20
09/29
01:40
09/29/20
01:40

Asian Market Update:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

General news
U.S. consumer confidence preview » 01:40
09/29/20
09/29
01:40
09/29/20
01:40

U.S. consumer confidence…

U.S. consumer confidence preview: consumer confidence is expected to rebound to 92.0 after unexpectedly tumbling -6.9 points to a 6-year low of 84.8 in August (even worse than the 85.7 pandemic hit in April) amid some worries over the loss of the extra unemployment benefits at the end of July. The index is way off of the 126.3 print from a year ago and was at an 18-year high of 137.9 in October 2018. It hit a recession-low of 25.3 in February of 2009. Analysts expect the present situation index to improve to 98.0 from 84.2 in August and a 7-year low of 68.4 in May, versus a 19-year high of 176.0 in August of 2019 and a recession-low of 20.2 in December of 2009. The expectations index should rise to 88.0 in September from 85.2, versus an 18-year high of 115.1 in October of 2018 and a recession-low of 27.3 in February of 2009. All of the available confidence measures were oscillating near historic highs before being crushed by COVID-19, and throughout the Q2 drop-backs and ensuing bounce, it's remarkable how firm the consumer measures have stayed relative to prior recessions.

General news
S&amp;P Case/Shiller home price preview » 01:40
09/29/20
09/29
01:40
09/29/20
01:40

S&amp;P Case/Shiller…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Initiation
Schroders initiated with an Underperform at RBC Capital » 21:12
09/28/20
09/28
21:12
09/28/20
21:12
SHNWF

Schroders

$0.00 /

+ (+0.00%)

RBC Capital analyst…

RBC Capital analyst Mandeep Jagnal initiated coverage of Schroders with an Underperform rating and 2,300 GBp price target. The company's business mix is the most negatively exposed to the trends of declining revenue margins and net outflows given that it has the highest proportion of actively managed assets under management at 91% of the total, the analyst tells investors in a research note.

ShowHide Related Items >><<
SHNWF Schroders
$0.00 /

+ (+0.00%)

08/03/20 Berenberg
Schroders price target raised to 3,200 GBp from 2,203 GBp at Berenberg
07/15/20 UBS
Schroders price target raised to 3,175 GBp from 2,950 GBp at UBS
07/09/20 Morgan Stanley
Schroders price target lowered to 2,610 GBp from 2,640 GBp at Morgan Stanley
06/25/20 Credit Suisse
Schroders downgraded to Underperform from Neutral at Credit Suisse
Upgrade
Estee Lauder upgraded to Neutral from Sell at Goldman Sachs » 21:08
09/28/20
09/28
21:08
09/28/20
21:08
EL

Estee Lauder

$215.58 /

+0.15 (+0.07%)

Goldman Sachs analyst…

Goldman Sachs analyst Jason English upgraded Estee Lauder to Neutral from Sell with a price target of $231, up from $147. The analyst cites the company's recent "Covid-19 related reset" of consensus expectations and also believes that a "sustained" Chinese consumption will be positive for its business. China growth is "appealing", though more "compelling" ways to invest behind it exist, English tells investors in a research note. The analyst further states that his prior Sell rating was predicated on China slowing from above-trend growth, and this prediction has "proven to be unequivocally wrong."

ShowHide Related Items >><<
EL Estee Lauder
$215.58 /

+0.15 (+0.07%)

EL Estee Lauder
$215.58 /

+0.15 (+0.07%)

09/04/20 Raymond James
Estee Lauder price target raised to $235 from $210 at Raymond James
09/03/20 Morgan Stanley
Brown-Forman price target raised to $66 from $56 at Morgan Stanley
08/26/20 Argus
Estee Lauder price target raised to $240 from $220 at Argus
08/24/20
Fly Intel: Top five analyst upgrades
EL Estee Lauder
$215.58 /

+0.15 (+0.07%)

EL Estee Lauder
$215.58 /

+0.15 (+0.07%)

EL Estee Lauder
$215.58 /

+0.15 (+0.07%)

EL Estee Lauder
$215.58 /

+0.15 (+0.07%)

Initiation
Wizz Air initiated with an Outperform at Bernstein » 21:00
09/28/20
09/28
21:00
09/28/20
21:00
WZZAF

Wizz Air

$0.00 /

+ (+0.00%)

Bernstein analyst Daniel…

Bernstein analyst Daniel Roeska initiated coverage of Wizz Air with an Outperform rating and 4,500 GBp price target. The analyst expects the company to emerge as a "clear winner" from the COVID-19 pandemic, calling the company the "last great growth story" in European aviation. Roeska states that Wizz Air has a "structural" growth runway for "at lease a decade" thanks to its efficient cost structure, balance sheet, and order book. The analyst adds that the company would be able to add more than 70% of its growth without "overwhelming the market".

ShowHide Related Items >><<
WZZAF Wizz Air
$0.00 /

+ (+0.00%)

09/23/20 Morgan Stanley
Wizz Air price target raised to 4,500 GBp from 3,800 GBp at Morgan Stanley
07/31/20 Berenberg
Wizz Air price target raised to 4,200 GBp from 4,000 GBp at Berenberg
07/30/20 JPMorgan
Wizz Air price target raised to 4,200 GBp from 4,150 GBp at JPMorgan
07/30/20 UBS
Wizz Air price target raised to 3,385 GBp from 3,255 GBp at UBS
Initiation
Epiroc initiated with a Buy at Societe Generale » 20:54
09/28/20
09/28
20:54
09/28/20
20:54
EPOKY

Epiroc

$0.00 /

+ (+0.00%)

Societe Generale analyst…

Societe Generale analyst Chand Debashis initiated coverage of Epiroc with a Buy rating and SEK 150 price target. The analyst likes the company's "niche" market positioning in mining equipment and its "proven" operating model. Debashis adds that Epiroc's "strong installed fleet" and "superior" service profile should support its revenue and profitability growth.

ShowHide Related Items >><<
EPOKY Epiroc
$0.00 /

+ (+0.00%)

09/18/20 Berenberg
Epiroc initiated with a Buy at Berenberg
07/24/20 JPMorgan
Epiroc price target raised to SEK 115 from SEK 105 at JPMorgan
07/24/20 Deutsche Bank
Epiroc price target raised to SEK 120 from SEK 105 at Deutsche Bank
07/24/20 Credit Suisse
Epiroc price target raised to SEK 105 from SEK 88 at Credit Suisse
Initiation
GreenPower Motor initiated with a Buy at BTIG » 20:50
09/28/20
09/28
20:50
09/28/20
20:50
GP

GreenPower Motor

$10.91 /

-0.31 (-2.76%)

BTIG analyst Gregory…

BTIG analyst Gregory Lewis initiated coverage of GreenPower Motor with a Buy rating and $25 price target. The analyst calls the company a "rising star" in the EV bus market, with its EV Star flagship vehicle already having been deployed across municipalities and airports across California with roughly 90 EV Stars currently on the road. Following its recent up-listing to NASDAQ. Lewis contends that GreenPower is well-positioned in the medium-term to ramp vehicle production.

ShowHide Related Items >><<
GP GreenPower Motor
$10.91 /

-0.31 (-2.76%)

GP GreenPower Motor
$10.91 /

-0.31 (-2.76%)

09/08/20 B. Riley FBR
GreenPower Motor initiated with a Buy at B. Riley FBR
09/02/20 Roth Capital
GreenPower Motor price target raised to $31 from $23.18 at Roth Capital
09/01/20 Roth Capital
GreenPower Motor price target raised to $31 from $23.18 at Roth Capital
GP GreenPower Motor
$10.91 /

-0.31 (-2.76%)

Initiation
Metso Outotec initiated with a Buy at Societe Generale » 20:46
09/28/20
09/28
20:46
09/28/20
20:46
OUKPY

Metso Outotec

$0.00 /

+ (+0.00%)

Societe Generale analyst…

Societe Generale analyst Chand Debashis initiated coverage of Metso Outotec with a Buy rating and EUR 8 price target. The analyst is positive on the company's merger with Outotec as making "strategic sense" in creating a market leader in mineral processing equipment. Debashis adds that he sees a "clear path" toward self-driven 12% adjusted EBITDA growth over 2019-2022 period.

ShowHide Related Items >><<
OUKPY Metso Outotec
$0.00 /

+ (+0.00%)

08/27/20 UBS
Metso Outotec price target raised to EUR 8.30 from EUR 6.20 at UBS
08/11/20 Morgan Stanley
Metso Outotec price target raised to EUR 6.90 from EUR 5.60 at Morgan Stanley
08/06/20 JPMorgan
Metso Outotec price target raised to EUR 8 from EUR 6.50 at JPMorgan
07/07/20 JPMorgan
Metso Outotec initiated with an Overweight at JPMorgan
Initiation
FLSmidth initiated with a Hold at Societe Generale » 20:43
09/28/20
09/28
20:43
09/28/20
20:43
FLIDF

FLSmidth

$0.00 /

+ (+0.00%)

Societe Generale analyst…

Societe Generale analyst Chand Debashis initiated coverage of FLSmidth with a Hold rating and DKK 210 price target. The analyst notes that the company's gradual shift toward being more mining focused is positive while offering a constructive outlook on the mining industry. Debashis adds however that the "challenging" cement market and FLSmidth's recent execution dampen his optimism.

ShowHide Related Items >><<
FLIDF FLSmidth
$0.00 /

+ (+0.00%)

08/31/20
Fly Intel: Top five analyst downgrades
08/31/20 Danske Bank
FLSmidth downgraded to Sell from Hold at Danske Bank
04/16/20 Credit Suisse
FLSmidth price target lowered to DKK 140 from DKK 207 at Credit Suisse
04/08/20 JPMorgan
FLSmidth price target lowered to DKK 205 from DKK 215 at JPMorgan
Hot Stocks
Salesforce CEO sells 30K shares of common stock » 20:33
09/28/20
09/28
20:33
09/28/20
20:33
CRM

Salesforce

$246.66 /

+3.95 (+1.63%)

In a regulatory filing,…

In a regulatory filing, Salesforce disclosed that its CEO Marc Benioff sold 30K shares of common stock on September 25th in a total transaction size of $7.3M.

ShowHide Related Items >><<
CRM Salesforce
$246.66 /

+3.95 (+1.63%)

CRM Salesforce
$246.66 /

+3.95 (+1.63%)

09/18/20 Baird
Salesforce benefitting from pandemic ecommerce burst, says Baird
08/26/20 Morgan Stanley
Salesforce price target raised to $275 from $195 at Morgan Stanley
08/26/20 JPMorgan
Salesforce price target raised to $250 from $200 at JPMorgan
08/26/20 Monness Crespi
Salesforce price target raised to $275 from $195 at Monness Crespi
CRM Salesforce
$246.66 /

+3.95 (+1.63%)

CRM Salesforce
$246.66 /

+3.95 (+1.63%)

CRM Salesforce
$246.66 /

+3.95 (+1.63%)

CRM Salesforce
$246.66 /

+3.95 (+1.63%)

Upgrade
Henkel upgraded to Buy from Neutral at Goldman Sachs » 19:42
09/28/20
09/28
19:42
09/28/20
19:42
HENKY

Henkel

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Olivier Nicolai upgraded Henkel to Buy from Neutral with a price target of EUR 102, up from EUR 80. The company's long-term growth profile below its peers, but its current low expectations are achievable and the risk/reward on the stock is attractive given the current valuation, the analyst tells investors in a research note. Nicolai adds that Henkel's margin "reset" has already happened while the company's balance sheet also "remains solid".

ShowHide Related Items >><<
HENKY Henkel
$0.00 /

+ (+0.00%)

09/08/20 Morgan Stanley
Henkel price target raised to EUR 74 from EUR 69 at Morgan Stanley
08/26/20 RBC Capital
Henkel price target raised to EUR 99 from EUR 98 at RBC Capital
08/18/20 Barclays
Henkel price target raised to EUR 89 from EUR 88 at Barclays
08/11/20 Berenberg
Henkel price target raised to EUR 85 from EUR 84 at Berenberg
HENKY Henkel
$0.00 /

+ (+0.00%)

Upgrade
L'Oreal upgraded to Buy from Neutral at Goldman Sachs » 19:40
09/28/20
09/28
19:40
09/28/20
19:40
LRLCY

L'Oreal

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Olivier Nicolai upgraded L'Oreal to Buy from Neutral with a price target of EUR 330, up from EUR 250. The analyst says the company's organic sales growth will recover at a fast pace, driven by its Asia market, skin care, and e-commerce initiatives. The overall beauty market has grown at 3%-5% over the last 20 years, and the company is set to emerge as a "structural winner" in an attractive category, Nicolai tells investors in a research note.

ShowHide Related Items >><<
LRLCY L'Oreal
$0.00 /

+ (+0.00%)

LRLCY L'Oreal
$0.00 /

+ (+0.00%)

09/17/20 Bryan Garnier
L'Oreal upgraded to Conviction Buy from Neutral at Bryan Garnier
08/20/20 Argus
L'Oreal price target raised to $76 from $68 at Argus
08/18/20 Barclays
L'Oreal price target raised to EUR 250 from EUR 236 at Barclays
08/18/20 RBC Capital
Estee Lauder price target raised to $194 from $173 at RBC Capital
LRLCY L'Oreal
$0.00 /

+ (+0.00%)

LRLCY L'Oreal
$0.00 /

+ (+0.00%)

Hot Stocks
Apollo Endosurgery discontinues furlough program » 19:34
09/28/20
09/28
19:34
09/28/20
19:34
APEN

Apollo Endosurgery

$1.38 /

-0.04 (-2.82%)

On September 23, 2020,…

On September 23, 2020, the company discontinued the employee furlough program previously announced on its Current Report on Form 8-K, filed with the SEC on April 20, 2020. Of the U.S.-based employees originally placed on furlough, 35 employees will not be recalled. The normalized annual compensation costs associated with these positions prior to previously announced compensation reductions due to the COVID-19 pandemic were approximately $5.0M. Total severance costs in the third quarter of 2020 are expected to be approximately $0.2M to $0.3M.

ShowHide Related Items >><<
APEN Apollo Endosurgery
$1.38 /

-0.04 (-2.82%)

APEN Apollo Endosurgery
$1.38 /

-0.04 (-2.82%)

04/28/20 Piper Sandler
Apollo Endosurgery downgraded to Neutral from Overweight at Piper Sandler
03/27/20 Piper Sandler
Apollo Endosurgery price target lowered to $4.50 from $5.50 at Piper Sandler
11/18/19 Piper Sandler
Apollo Endosurgery transferred with an Overweight rating at Piper Jaffray
11/18/19 Piper Sandler
Apollo Endosurgery transferred with an Overweight rating at Piper Jaffray
APEN Apollo Endosurgery
$1.38 /

-0.04 (-2.82%)

Earnings
Apollo Endosurgery sees Q3 revenue above Q3 of last year » 19:32
09/28/20
09/28
19:32
09/28/20
19:32
APEN

Apollo Endosurgery

$1.38 /

-0.04 (-2.82%)

In a regulatory 8K filing…

In a regulatory 8K filing released earlier this evening, the company states: "On August 4, 2020, Apollo Endosurgery, Inc., or the company, reported its financial results for the second quarter of 2020 and provided a revenue outlook for the third quarter of 2020. At that time, during the earnings conference call, the company's management commented on COVID-19 risks and its historical experience of lower procedure volumes in the third quarter especially in its OUS markets. As a result, management indicated that third quarter sales were expected to be higher sequentially compared to the second quarter of 2020, but still below the third quarter of 2019. Sales in the third quarter of 2019 were $11.3 million. Since then, third quarter 2020 revenue has exceeded those expectations. As a result, the company expects third quarter 2020 revenue to exceed its third quarter 2019 revenue."

ShowHide Related Items >><<
APEN Apollo Endosurgery
$1.38 /

-0.04 (-2.82%)

APEN Apollo Endosurgery
$1.38 /

-0.04 (-2.82%)

04/28/20 Piper Sandler
Apollo Endosurgery downgraded to Neutral from Overweight at Piper Sandler
03/27/20 Piper Sandler
Apollo Endosurgery price target lowered to $4.50 from $5.50 at Piper Sandler
11/18/19 Piper Sandler
Apollo Endosurgery transferred with an Overweight rating at Piper Jaffray
11/18/19 Piper Sandler
Apollo Endosurgery transferred with an Overweight rating at Piper Jaffray
Hot Stocks
Ascendis Pharma announces 6-month data from ph.2 study of TransCon PTH » 19:07
09/28/20
09/28
19:07
09/28/20
19:07
ASND

Ascendis Pharma

$151.83 /

-2.2 (-1.43%)

Ascendis Pharma announced…

Ascendis Pharma announced preliminary six-month results from the open-label extension portion of PaTH Forward, a global phase 2 trial evaluating the safety, tolerability and efficacy of TransCon PTH in adult subjects with hypoparathyroidism, or HP. Preliminary six-month results from the PaTH Forward OLE demonstrated: 91% of all subjects eliminated standard of care, including 76% who eliminated all supplements. 86% of all subjects normalized or reduced by 50% 24-hour urine calcium. 71% of all subjects achieved a response on the composite endpoint of (1) serum calcium in the normal range, (2) independence from active vitamin D, (3) taking less than or equal to500 mg/day of calcium supplements, and (4) 24-hour urine calcium in the normal range or 50% reduction from baseline, including 74% of subjects who were randomized to TransCon PTH. The company submitted an amendment to its investigational new drug application with the FDA to initiate the U.S. sites of the PaTHway phase 3 clinical trial evaluating the safety, tolerability and efficacy of TransCon PTH in adults with HP following discussions with FDA and European regulatory authorities. The company expects to file the clinical trial application for the European arm later this year. The double-blind, placebo-controlled trial is expected to enroll approximately 76 subjects at sites in North America and Europe in order to obtain 68 evaluable subjects.

ShowHide Related Items >><<
ASND Ascendis Pharma
$151.83 /

-2.2 (-1.43%)

ASND Ascendis Pharma
$151.83 /

-2.2 (-1.43%)

09/14/20 JPMorgan
Ascendis Pharma resumed with an Overweight at JPMorgan
08/31/20 Cantor Fitzgerald
Cantor says Ascendis has important catalyst coming with TransCon PTH data
05/20/20 Credit Suisse
Ascendis Pharma price target raised to $154 from $149 at Credit Suisse
05/20/20 Oppenheimer
Ascendis Pharma price target lowered to $208 from $219 at Oppenheimer
ASND Ascendis Pharma
$151.83 /

-2.2 (-1.43%)

  • 08
    Jul
ASND Ascendis Pharma
$151.83 /

-2.2 (-1.43%)

General News
Pelosi says Democrats introducing new COVID-19 relief package » 18:59
09/28/20
09/28
18:59
09/28/20
18:59
SPY

SPDR S&P 500 ETF Trust

$334.20 /

+5.51 (+1.68%)

, SPX

S&P 500

$0.00 /

+ (+0.00%)

According to a statement…

According to a statement released by House Speaker Nancy Pelosi's office, Democratic lawmakers are unveiling an updated Heroes Act that serves as the party's proffer to Republicans to come to negotiations to address the health and economic catastrophe in our country. "This $2.2T Heroes Act provides the absolutely needed resources to protect lives, livelihoods and the life of our democracy over the coming months," the statement reads. "It includes new funding needed to avert catastrophe for schools, small businesses, restaurants, performance spaces, airline workers and others. It has been more than four months since House Democrats sent the GOP Senate $3.4T in desperately needed coronavirus relief grounded in science and data, and Leader McConnell hit the pause button. In our negotiations with the White House since then, Democrats offered to come down a trillion dollars if Republicans would come up a trillion dollars. Then, we offered to come down $200B more, even as the health and economic crisis has worsened and the needs have only grown." Reference Link

ShowHide Related Items >><<
SPY SPDR S&P 500 ETF Trust
$334.20 /

+5.51 (+1.68%)

SPY SPDR S&P 500 ETF Trust
$334.20 /

+5.51 (+1.68%)

09/01/20
Fed's Brainard says monetary policy to pivot from stabilization to accommodation
08/17/20 Goldman Sachs
Goldman boosts end of 2020 S&P 500 target to 3,600 from 3,000
06/04/20 Keefe Bruyette
Mattis rebuke 'wake up call' for stock market, says Keefe Bruyette
03/11/20 Goldman Sachs
Goldman Sachs believes the S&P 500 bull market will soon end
SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$334.20 /

+5.51 (+1.68%)

SPY SPDR S&P 500 ETF Trust
$334.20 /

+5.51 (+1.68%)

SPY SPDR S&P 500 ETF Trust
$334.20 /

+5.51 (+1.68%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$334.20 /

+5.51 (+1.68%)

SPX S&P 500
$0.00 /

+ (+0.00%)

Hot Stocks
Boeing awarded $249M Missile Defense Agency contract modification » 18:35
09/28/20
09/28
18:35
09/28/20
18:35
BA

Boeing

$166.20 /

+10.13 (+6.49%)

Boeing was awarded a…

Boeing was awarded a $249M undefinitized contract modification to a previously awarded on the Ground-based Midcourse Defense Development and Sustainment contract, or DSC. The scope of work under the current DSC includes development, fielding, test, systems engineering, integration and configuration management, equipment manufacturing and refurbishment, training and operations and sustainment for the GMD weapon system and associated support facilities. Under this undefinitized modification, the Missile Defense Agency executes the Service Life Extension Program, or SLEP, upgrade of ground based interceptors, or GBI; the upgrade and repair of specialized production equipment necessary to support SLEP activities; systems engineering to support CE-I fleet readiness; cybersecurity activities and the production of a payload to support system testing requirements. The value of this contract, including options, is increased from $11.52B to $11.77B. The period of performance is from September 24 to December 31, 2022. This acquisition was executed on a sole-source basis. FY20 research, development, test and evaluation funds in the amount of $45.69M have been obligated at the time of award. The Missile Defense Agency is the contracting activity.

ShowHide Related Items >><<
BA Boeing
$166.20 /

+10.13 (+6.49%)

BA Boeing
$166.20 /

+10.13 (+6.49%)

09/28/20
Fly Intel: Top five analyst upgrades
09/28/20 Alembic Global
Alembic upgrades Boeing with 737 MAX return 'finally in sight'
09/28/20 Alembic Global
Boeing upgraded to Overweight from Neutral at Alembic Global
09/24/20 Wolfe Research
Boeing upgraded to Peer Perform from Underperform at Wolfe Research
BA Boeing
$166.20 /

+10.13 (+6.49%)

BA Boeing
$166.20 /

+10.13 (+6.49%)

BA Boeing
$166.20 /

+10.13 (+6.49%)

BA Boeing
$166.20 /

+10.13 (+6.49%)

Hot Stocks
Cable One to acquire 45% minority stake in MBI for about $574.1M in cash » 18:32
09/28/20
09/28
18:32
09/28/20
18:32
CABO

Cable One

$1,755.00 /

+24.06 (+1.39%)

Mega Broadband…

Mega Broadband Investments Holdings and Cable One announced that they have entered into a definitive agreement providing for a strategic investment by Cable One in MBI. Cable One will purchase a 45% minority stake in MBI from affiliates of GTCR, a private equity firm, for approximately $574.1M in cash, subject to adjustment for certain new debt incurrences and transaction expenses. In addition to the minority stake it will acquire, Cable One will have the right to purchase the remaining interests in MBI at a predetermined multiple of earnings beginning in 2023. The transaction is expected to be completed during the fourth quarter. Cable One expects to fund the transaction through cash on hand.

ShowHide Related Items >><<
CABO Cable One
$1,755.00 /

+24.06 (+1.39%)

CABO Cable One
$1,755.00 /

+24.06 (+1.39%)

08/11/20 Truist
Cable One price target raised to $2,000 from $1,850 at Truist
05/12/20 KeyBanc
Cable One price target raised to $2,105 from $1,968 at KeyBanc
05/12/20 Truist
Cable One price target raised to $1,850 from $1,600 at SunTrust
04/20/20 Cowen
Cable One initiated with a Market Perform at Cowen
CABO Cable One
$1,755.00 /

+24.06 (+1.39%)

  • 20
    May
Hot Stocks
Honeywell awarded $258.66M Army contract » 18:31
09/28/20
09/28
18:31
09/28/20
18:31
HON

Honeywell

$164.42 /

+2.87 (+1.78%)

Honeywell was awarded a…

Honeywell was awarded a $258.66M firm-fixed-price contract for overhaul/repair of T55-GA-714A engines for the CH-47 Chinook. Bids were solicited via the internet with two received. Work locations and funding will be determined with each order, with an estimated completion date of July 31, 2021. The U.S. Army Contracting Command is the contracting activity.

ShowHide Related Items >><<
HON Honeywell
$164.42 /

+2.87 (+1.78%)

HON Honeywell
$164.42 /

+2.87 (+1.78%)

08/11/20 RBC Capital
Honeywell downgraded to Sector Perform from Outperform at RBC Capital
08/11/20 RBC Capital
Honeywell downgraded to Sector Perform from Outperform at RBC Capital
07/28/20 Argus
Honeywell price target raised to $165 at Argus on continued product diversity
07/27/20 JPMorgan
Honeywell price target raised to $185 from $177 at JPMorgan
HON Honeywell
$164.42 /

+2.87 (+1.78%)

HON Honeywell
$164.42 /

+2.87 (+1.78%)

HON Honeywell
$164.42 /

+2.87 (+1.78%)

HON Honeywell
$164.42 /

+2.87 (+1.78%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.